Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 crossover trial of sebetralstat for on-demand treatment of hereditary angioedema attacks
2021-001226-21Phase 3Completed
- Sponsor
- KalVista Pharmaceuticals
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sebetralstat in hereditary angioedema (HAE) (3 arms), sponsored by KalVista Pharmaceuticals. Primary endpoint: Patient Global Impression of Change: time to beginning of symptom relief. Started Mar 2022; status: completed.
02
Drugs
sebetralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2021-001226-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001226-21.